Omalizumab reduces asthma exacerbations among responders at 28 weeks: the INNOVATE study

被引：0
|
作者：
Bousquet, J. [1 ]
Humbert, M. [2 ]
Rao, S. [3 ]
Pethe, A. [4 ]
Manga, V [3 ]
机构：
[1] Hop Arnaud de Villeneuve, Serv Pneumol, Montpellier, France
[2] Univ Paris 11, Hop Bicetre, Paris, France
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Healthcare, Hyderabad, Andhra Pradesh, India
来源：
ALLERGY | 2014年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
1445
引用
收藏
页码：519 / 519
页数：1
相关论文
共 50 条
  • [41] OMALIZUMAB ADHERENCE AMONG NEW USERS IN THE FIRST TWO YEARS IN AN OBSERVATIONAL STUDY OF PATIENTS WITH MODERATE-TO-SEVEREALLERGIC ASTHMA.
    Miller, M. K.
    Yegin, A.
    Trzaskoma, B.
    Eisner, M. D.
    Zazzali, J. L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A34 - A35
  • [42] Nocturnal emergency department visits, duration of symptoms and risk of hospitalisation among adults with asthma exacerbations: a multicentre observational study
    Yasuda, Hideto
    Hagiwara, Yusuke
    Watase, Hiroko
    Hasegawa, Kohei
    BMJ OPEN, 2016, 6 (08):
  • [43] Dupilumab Reduces Severe Exacerbations and Improves Lung Function Regardless of Baseline Bronchodilator Reversibility in Patients with Uncontrolled Moderate-to-Severe Asthma Enrolled in the LIBERTY ASTHMA QUEST Study
    Pavord, I.
    Castro, M.
    Rabe, K. F.
    Hanania, N. A.
    Papi, A.
    FitzGerald, J. M.
    Rice, M. S.
    Rowe, P.
    Lu, Y.
    Amin, N.
    Staudinger, H. W.
    Graham, N. M. H.
    Teper, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [44] DUPILUMAB REDUCES SEVERE ASTHMA EXACERBATION RATES AND IMPROVES LUNG FUNCTION ACROSS A RANGE OF PRIOR EXACERBATIONS IN PATIENTS WITH ELEVATED TYPE 2 BIOMARKERS: THE LIBERTY ASTHMA QUEST STUDY
    Katelaris, Constance H.
    Douglass, Jo A.
    Ford, Linda B.
    Rice, Megan S.
    Moody, Jana
    Djandji, Michel
    Radwan, Amr
    Rowe, Paul
    Deniz, Yamo
    Amin, Nikhil
    Teper, Ariel
    INTERNAL MEDICINE JOURNAL, 2019, 49 : 34 - 35
  • [45] DUPILUMAB REDUCES EXACERBATIONS AND IMPROVES LUNG FUNCTION IN UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA PATIENTS REGARDLESS OF PRIOR EXACERBATION HISTORY IN THE PHASE 3 LIBERTY ASTHMA QUEST STUDY
    Pavord, I.
    Ford, L. B.
    Corren, J.
    Kuna, P.
    Dong, Q.
    Staudinger, H.
    Maroni, J.
    Rowe, P.
    Rout, R.
    Amin, N.
    Akinlade, B.
    Graham, N. M. H.
    Teper, A.
    THORAX, 2018, 73 : A121 - A122
  • [46] Tezepelumab Reduces Exacerbations Across All Seasons In Patients With Severe, Uncontrolled Asthma With Seasonal Allergy: Results From The Phase 3 NAVIGATOR Study
    Corren, Jonathan
    Lindsley, Andrew
    Spahn, Joseph
    Cook, Bill
    Griffiths, Janet
    Martin, Nicole
    Colice, Gene
    Pavord, Ian
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB194 - AB194
  • [47] DUPILUMAB REDUCES SEVERE EXACERBATIONS ACROSS BASELINE DISEASE CHARACTERISTICS IN PATIENTS WITH ELEVATED BASELINE TYPE 2 BIOMARKERS: THE LIBERTY ASTHMA QUEST STUDY
    Busse, W. W.
    Munoz, X.
    Casale, T. B.
    Paggiaro, P.
    Castro, M.
    Tohda, Y.
    Rice, M. S.
    Deniz, Y.
    Rowe, P.
    Amin, N.
    Teper, A.
    THORAX, 2019, 74 : A21 - A22
  • [48] Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study
    Woehlk, Christian
    Von Bullow, Anna
    Ghanizada, Muzhda
    Sondergaard, Marianne Baastrup
    Hansen, Susanne
    Porsbjerg, Celeste
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60 (05)
  • [49] An Add-on Reliever-Triggered Inhaled Corticosteroid Strategy Reduces Severe Asthma Exacerbations in a Real-World Study of African American/Black and Hispanic/Latinx Patients with Asthma
    Cardet, J. C.
    Pace, W. D.
    Carroll, J. K.
    Fuhlbrigge, A. L.
    She, L.
    Rockhold, F. W.
    Maher, N. E.
    Fagan, M.
    Forth, V. E.
    Hernandez, P. Arias
    Kruse, J.
    Manning, B. K.
    Rodriguez-Louis, J.
    Shields, J. B.
    Ericson, B.
    Colon-Moya, A. D.
    Coyne-Beasley, T.
    Hammer, G. M.
    Kaplan, B. M.
    Madison, S.
    Rand, C. S.
    Robles, J.
    Thompson, O.
    Wechsler, M. E.
    Wisnivesky, J. P.
    Mckee, M. D.
    Jariwala, S. P.
    Jerschow, E.
    Busse, P. J.
    Kaelber, D. C.
    Nazario, S.
    Hernandez, M. L.
    Apter, A. J.
    Chang, K.
    Pinto-Plata, V.
    Stranges, P. M.
    Hurley, L. H.
    Trevor, J.
    Casale, T. B.
    Chupp, G.
    Riley, I. L.
    Shenoy, K. V.
    Pasarica, M.
    Candelario, R. A. Calderon
    Tapp, H.
    Baydur, A.
    Yawn, B. P.
    Israel, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [50] Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients across prior historical exacerbation subgroups in the phase 3 LIBERTY ASTHMA QUEST study
    Ford, L.
    Corren, J.
    Kuna, P.
    Dong, Q.
    Staudinger, H.
    Maroni, J.
    Rowe, P.
    Amin, N.
    Pirozzi, G.
    Ruddy, M.
    Akinlade, B.
    Graham, N. M. H.
    Teper, A.
    ALLERGY, 2018, 73 : 464 - 465
12345